Clinical Application of Established and Emerging Biomarkers for Cardiopulmonary Diseases

Dear Colleagues,

With a worldwide prevalence of 7.4%, chronic respiratory conditions have a growing impact at all levels of economic and health systems, relevant social costs, and new healthcare needs in a population that is increasingly living longer. The impact of cardiovascular diseases appears to be even more significant, as stated by the World Health Organization (WHO), which reports that they are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. The close interconnection between respiratory and cardiovascular pathologies has recently become an area of great clinical and scientific interest, increasing the need for new diagnostic and prognostic tools for the adequate assessment of comorbidities and overall clinical complexity.

Using both clinical methods and laboratory analyses of biological matrices, an increasing number of biomarkers have been identified to improve the risk stratification and adequate monitoring of the pharmacological and rehabilitative therapies recommended in cardiopulmonary diseases.

Using both clinical methods and laboratory analyses of biological matrices, an increasing number of biomarkers have been identified in order to improve the risk stratification and adequate monitoring of the pharmacological as well as rehabilitative therapies recommended in respiratory diseases.

This Special Issue aims to collect new evidence on the use of established and emerging biomarkers for cardiopulmonary diseases, which include, but are not limited, to severe asthma, chronic obstructive pulmonary disease, interstitial lung disease, heart failure, myocardial infarction, and stroke.

Dr. Pasquale Ambrosino
Prof. Dr. Mauro Maniscalco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.